

Special Issue

Current Status and Future Directions in Non-Small Cell Lung Cancer Therapy

Message from the Guest Editors

The therapeutic strategies for non-small cell lung cancer have evolved rapidly in recent years. For patient with targetable oncogenes, including EGFR mutations, ALK/ROS1/RET fusions, targeted therapy with small molecular tyrosine kinase inhibitors, have demonstrated superior efficacy over classical chemotherapy. Great progress has also been achieved in some rare oncogenes, including BRAFV600E mutations, HER2 mutations, EGFR 20ins, NTRK fusions et al. On the other hand, for patients without oncogenic drivers, immune checkpoint inhibitors, targeting the PD-1/PD-L1 axis, either as monotherapy or in combination with chemotherapy, have been the standard of care and have resulted in long-term survival in a subset of patients. Despite these advancements, acquired resistance inevitably occurs. A better understanding of the mechanisms of resistance to therapy is essential to further expand the survival benefits. In the future, we believe novel targets and novel agents (i.e. bispecific antibody, antibody–drug conjugate) will help translating this malignancy into a “chronic disease”.

Guest Editors

Dr. Fei Zhou

Department of Medical Oncology, Shanghai Pulmonary Hospital, Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai 200433, China

Dr. Xiaoxia Chen

Department of Medical Oncology, Shanghai Pulmonary Hospital, Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai 200433, China

Deadline for manuscript submissions

closed (20 October 2023)



Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 2.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/156633

Journal of Clinical Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jcm@mdpi.com

mdpi.com/journal/

jcm





Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 2.9
CiteScore 5.2
Indexed in PubMed



[mdpi.com/journal/
jcm](https://mdpi.com/journal/jcm)



About the Journal

Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's* (JCM) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

Editors-in-Chief

Prof. Dr. Emmanuel Andr s

Internal Medicine Department, University Hospital Strasbourg, 67000
Strasbourg, France

Prof. Dr. Kent Doi

Department of Emergency and Critical Care Medicine, University of
Tokyo, Tokyo, Japan

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1
(General Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.7 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).